ES478199A1 - Un procedimiento para la preparacion de etalazinas. - Google Patents

Un procedimiento para la preparacion de etalazinas.

Info

Publication number
ES478199A1
ES478199A1 ES478199A ES478199A ES478199A1 ES 478199 A1 ES478199 A1 ES 478199A1 ES 478199 A ES478199 A ES 478199A ES 478199 A ES478199 A ES 478199A ES 478199 A1 ES478199 A1 ES 478199A1
Authority
ES
Spain
Prior art keywords
cardiac
compounds
heart failure
piperidinophthalazines
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES478199A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp SRL filed Critical Pfizer Corp SRL
Publication of ES478199A1 publication Critical patent/ES478199A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención se refiere a agentes terapéuticos, que son nuevos derivados de la ftalazina, y especialmente se refiere a estos derivados con un grupo piperidino sustituido en la posición 1. Los compuestos de la invención son inhibidores de la fosfodiesterasa y estimulantes cardíacos, de los que una clase preferida aumenta selectivamente la fuerza de la contracción mio cardial sin producir aumentos significativos del ritmo cardiaco. Los compuestos son útiles en el tratamiento curativo o profiláctico de las condiciones cardíacas , como fallo cardiaco congestivo, angina de pecho arritmias cardiacas y fallo cardíaco agudo.
ES478199A 1977-06-03 1979-03-01 Un procedimiento para la preparacion de etalazinas. Expired ES478199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2358277 1977-06-03

Publications (1)

Publication Number Publication Date
ES478199A1 true ES478199A1 (es) 1980-01-16

Family

ID=10198020

Family Applications (4)

Application Number Title Priority Date Filing Date
ES470470A Expired ES470470A1 (es) 1977-06-03 1978-06-02 Un procedimiento para la preparacion de ftalazinas
ES478201A Expired ES478201A1 (es) 1977-06-03 1979-03-01 Un procedimiento para la preparacion de ftalazinas.
ES478199A Expired ES478199A1 (es) 1977-06-03 1979-03-01 Un procedimiento para la preparacion de etalazinas.
ES478200A Expired ES478200A1 (es) 1977-06-03 1979-03-01 Un procedimiento para la preparacion de ftalazinas.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES470470A Expired ES470470A1 (es) 1977-06-03 1978-06-02 Un procedimiento para la preparacion de ftalazinas
ES478201A Expired ES478201A1 (es) 1977-06-03 1979-03-01 Un procedimiento para la preparacion de ftalazinas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES478200A Expired ES478200A1 (es) 1977-06-03 1979-03-01 Un procedimiento para la preparacion de ftalazinas.

Country Status (29)

Country Link
US (1) US4289772A (es)
JP (1) JPS5416488A (es)
AR (2) AR222013A1 (es)
AT (2) AT362792B (es)
AU (1) AU505373B1 (es)
BE (1) BE867727A (es)
CA (1) CA1111850A (es)
DD (1) DD137355A5 (es)
DE (1) DE2824064A1 (es)
DK (1) DK248078A (es)
EG (1) EG13527A (es)
ES (4) ES470470A1 (es)
FI (1) FI781753A7 (es)
FR (1) FR2392986A1 (es)
GB (1) GB2000136B (es)
GR (1) GR74402B (es)
HU (1) HU179745B (es)
IL (1) IL54842A (es)
IN (3) IN148482B (es)
IT (1) IT1094944B (es)
LU (1) LU79761A1 (es)
NL (1) NL7806016A (es)
NO (1) NO781935L (es)
NZ (1) NZ187453A (es)
PL (3) PL116437B1 (es)
PT (1) PT68126A (es)
SE (1) SE7806519L (es)
SU (2) SU856383A3 (es)
ZA (1) ZA783183B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370328A (en) * 1977-11-03 1983-01-25 Pfizer Inc. Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines
IL59619A0 (en) * 1979-03-28 1980-06-30 Pfizer Phthalazine derivatives,their preparation and pharmaceutical compositions containing them
PL129174B1 (en) * 1980-03-01 1984-04-30 Wyeth John & Brother Ltd Process for preparing novel derivatives of piperidine
GB8320958D0 (en) * 1983-08-03 1983-09-07 Pfizer Ltd Quinazoline cardiac stimulants
US5001125A (en) * 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
US4882354A (en) * 1987-12-16 1989-11-21 Norwich Eaton Pharmaceuticals, Inc. N-hydroxy-5-phenyl-2-furancarboximidamides useful as cardiotonic agents
US5300515A (en) * 1991-01-31 1994-04-05 Kyorin Pharmaceutical Co., Ltd. Carbamic acid derivatives and method for preparing the same
JP3169188B2 (ja) * 1991-01-31 2001-05-21 杏林製薬株式会社 カルバミン酸誘導体及びその製造方法
EP0621267A1 (en) * 1993-04-07 1994-10-26 Shell Internationale Researchmaatschappij B.V. Spiropiperidine derivatives and their use as fungicides
US5728712A (en) * 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
US6288064B1 (en) * 1996-08-20 2001-09-11 Eisai Co., Ltd. Remedy for erection failure comprising fused pyridazine compound
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
JP4554364B2 (ja) * 2002-08-16 2010-09-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ インテグリンと選択的に結合するピペリジニル化合物
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
US20060019975A1 (en) * 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
BRPI0707223A2 (pt) * 2006-01-27 2011-04-26 Pfizer Prod Inc compostos de derivados de aminoftalazina
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
TW200815353A (en) 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP1900731A1 (de) * 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
EP1903037A1 (de) * 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioharnstoffe als Modulatoren des EP2-Rezeptors
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
BRPI0815658A2 (pt) 2007-08-07 2015-02-18 Hoffmann La Roche Aril-éter pirrolidina como antagonistas do receptor nk3
AU2008290634B2 (en) 2007-08-22 2012-12-06 F. Hoffmann-La Roche Ag Pyrrolidine aryl-ether as NK3 receptor antagonists
KR101174980B1 (ko) * 2007-09-14 2012-08-17 에프. 호프만-라 로슈 아게 Ｎｋ３ 수용체 길항제로서의 피페리딘 유도체
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
CN116349204A (zh) 2020-10-13 2023-06-27 奋进生物医药公司 治疗纤维化的方法
CN113087654B (zh) * 2021-04-15 2022-12-23 苏州昊帆生物股份有限公司 哌啶-4-丁胺的制备方法
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
GB1199768A (en) 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
GB1460389A (en) 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants

Also Published As

Publication number Publication date
ATA305080A (de) 1980-12-15
IL54842A (en) 1982-01-31
PL207337A1 (pl) 1979-06-04
CA1111850A (en) 1981-11-03
FI781753A7 (fi) 1978-12-04
IN149550B (es) 1982-01-16
DE2824064A1 (de) 1978-12-14
IN149973B (es) 1982-06-19
GB2000136A (en) 1979-01-04
ES478201A1 (es) 1980-02-01
NZ187453A (en) 1980-12-19
PL116437B1 (en) 1981-06-30
HU179745B (en) 1982-12-28
DD137355A5 (de) 1979-08-29
GR74402B (es) 1984-06-28
LU79761A1 (fr) 1980-01-22
ES470470A1 (es) 1979-09-01
AT362792B (de) 1981-06-10
BE867727A (fr) 1978-12-01
AT363096B (de) 1981-07-10
SU856383A3 (ru) 1981-08-15
IN148482B (es) 1981-03-07
SU862826A3 (ru) 1981-09-07
ATA400878A (de) 1980-11-15
US4289772A (en) 1981-09-15
DK248078A (da) 1978-12-04
NL7806016A (nl) 1978-12-05
PL116420B1 (en) 1981-06-30
AR223999A1 (es) 1981-10-15
NO781935L (no) 1978-12-05
SE7806519L (sv) 1978-12-04
IL54842A0 (en) 1978-08-31
GB2000136B (en) 1982-01-06
AR222013A1 (es) 1981-04-15
JPS5538351B2 (es) 1980-10-03
FR2392986B1 (es) 1982-07-16
PL113208B1 (en) 1980-11-29
ZA783183B (en) 1979-06-27
FR2392986A1 (fr) 1978-12-29
JPS5416488A (en) 1979-02-07
PT68126A (en) 1978-07-01
AU505373B1 (en) 1979-11-15
EG13527A (en) 1981-12-31
IT1094944B (it) 1985-08-10
ES478200A1 (es) 1980-01-01
IT7824106A0 (it) 1978-06-01

Similar Documents

Publication Publication Date Title
ES474763A1 (es) Un procedimiento para la preparacion de nuevos derivados de quinazolona.
Josephson et al. Recurrent sustained ventricular tachycardia. 1. Mechanisms.
UY23835A1 (es) Procedimiento para la preparacion de compuesto de acilo
IT7827067A0 (it) Derivati della 3,4,5-triidrossipipe ridina, processi per la loro produzione e loro impiego.
IT7825415A0 (it) Derivati di acidi fenossi-fenil-tip-alcan-carbossilici, procedimento per la loro preparazione e loro impiego.
ES8704926A1 (es) Un procedimiento para la preparacion de derivados de benzotiazol y benzotiofeno
ES2059491T3 (es) Derivados de indol con anillos condensados.
SE7806519L (sv) Terapeutiska medel
ES468077A1 (es) Un procedimiento para la preparacion de derivados de 5-(l- diaril-metil)-1 piperazinilalquil)bencimidazol
EP0424525A4 (en) Novel amines and their use.
BE762580A (fr) Nouveaux derives de 1,4-dihydropyridine
ES2072263T3 (es) Derivados de 4-aminopiridina.
ES2038074A1 (es) Nuevos derivados de benzimidazol, su preparacion y su aplicacion como medicamentos.
NL7903616A (nl) Blik uit elektrolytisch verchroomd staal.
NL175883C (nl) Transveneuze inplanteerbare hartstimulatorelektrode.
ES2127875T3 (es) Bencenosulfonil-ureas y -tioureas sustituidas con amino, procedimiento para su preparacion y su utilizacion como productos farmaceuticos.
ES2091283T3 (es) Derivados de isocromano.
IT1037748B (it) Procedimento per la produzione di biossido di titanio
IT8020992A0 (it) Procedimento per mantenere i parametri preselezionati del fango di perforazione.
IT1058755B (it) Procedimento per la fabbricazione di anodi sinterizzati per condensatori elettrolitici
ES2066905T3 (es) Heterociclos substituidos con amino como inhibidores de renina.
IT996763B (it) Bagno per la deposizione di rame duttile senza impiego dell elettri cita
GT197749830A (es) Procedimiento para preparar cianoguanidinas
IT1104109B (it) Procedimento per la produzione di derivati del 2,1,3-tiadiazin-4-on-2,2-biossido
IT1013087B (it) Procedimento per la produzione di bis bromometil tetraolorobenzoli e loro impiego come agenti ignifuganti